American College of Clinical Pharmacy
      Search      Cart
         

PSAP in JACCP - Part I: PSAP Live: Updates from 2022 Book 1 (Cardiology) and Part II: Interactive Case: Critical Evaluation of Kidney Function - 2023 October


Member Price:
$29.95
Nonmember Price:
$29.95

Faculty Information

PSAP in JACCP features are developed from activities presented as part of the Pharmacotherapy Self-Assessment Program (PSAP).

Part I: PSAP Live: Updates from 2022 Book 1 (Cardiology)

This feature was developed from a live program presented in October 2022 at the ACCP Global Conference in San Francisco.

  • Recorded Webcast: Click here to access the Recorded webcast.
  • PDF Transcript: Click here to access the PDF Transcript.
Part II: Critical Evaluation of Kidney Function

This feature was developed from an interactive case presented in PSAP 2023 Book 1 (Endocrinology and Nephrology).

  • Interactive case: Click here to access the interactive case.

Author - Reviewer Information

Part I: PSAP Live: Updates from 2022 Book 1 (Cardiology)

Presenters: Craig J. Beavers, Pharm.D., FCCP, FACC, FAHA, BCCP, BCPS-AQ Cardiology, CACP; Kelly M. Rudd, Pharm.D., FCCP, BCPS; and Stephanie Dwyer Kaluzna, Pharm.D., BCCP
Reviewed by: Stormi E. Gale, Pharm.D., BCPS, BCCP; Candace Bryant, Pharm.D., BCPS; and A. Joshua Roberts, Pharm.D., BCCP, BCPS, AACC

Part II: Interactive Case: Critical Evaluation of Kidney Function

Authors: Ayesha M. Khan, Pharm.D., BCPS; and Gary D. Peksa, Pharm.D., MBA, BCPS
Reviewed by: Wendy St. Peter, Pharm.D.; and Bryn Lindley, Pharm.D., BCPS

Target Audience and Learning Objectives

Part I: PSAP Live: Updates from 2022 Book 1 (Cardiology)

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists whose practice involves the direct care and management of patients living with one or more common cardiac conditions or disorders.

Learning Objectives

  1. Distinguish the incidence, pathophysiology, risk factors, and clinical presentation associated with heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF).
  2. Examine the clinical efficacy and safety data associated with agents recommended for the treatment of HFpEF.
  3. Develop a pharmacologic treatment plan for HFrEF and HFpEF that optimizes the use of guideline-directed medical therapy.
  4. Distinguish the thrombotic pathophysiology of antiphospholipid syndrome (APS).
  5. Evaluate available evidence pertaining to the use of anticoagulants in patients with APS.
  6. Develop an appropriate guideline-driven pharmacotherapeutic treatment plan for a patient with APS.
  7. Design an antithrombotic treatment plan for a patient undergoing coronary stenting.
  8. Analyze recent literature surrounding modified regimens of dual antiplatelet therapy in patients with coronary artery disease and acute coronary syndromes.
  9. Distinguish between the various antithrombotic treatment regimens indicated for patients undergoing transcatheter aortic valve implantation.
Part II: Interactive Case: Critical Evaluation of Kidney Function

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists whose practice involves the direct care and management of patients living with diabetes, CKD, or other specialized endocrinologic considerations.

Learning Objectives

  1. Assess different methods in evaluating kidney function.
  2. Develop patient care plans that equitably and safely address patients with kidney dysfunction.
  3. Evaluate the influence of patient-specific factors on drug disposition.
  4. Distinguish factors that must be considered when designing a drug dosing regimen for a patient with kidney impairment.

Disclosure of Potential Conflicts of Interest

Part I: PSAP Live: Updates from 2022 Book 1 (Cardiology)

Nothing to disclose: Craig J. Beavers, Candace Bryant, Stormi E. Gale, Stephanie Dwyer Kaluzna, A. Joshua Roberts, Kelly M. Rudd

Part II: Interactive Case: Critical Evaluation of Kidney Function

Consultancies: Wendy St. Peter (Glaxosmithkline)
Nothing to disclose: Ayesha M. Khan, Bryn Lindley, Gary D. Peksa

Continuing Pharmacy Education and Recertification Instructions

Available CPE/Recertification credits: Anyone who purchases, successfully completes, and passes the required posttests for this feature can earn up to 3.0 contact hours of CPE/Recertification credit.

Part I: PSAP Live: Updates from 2022 Book 1 (Cardiology)

Universal Activity Number: 0217-0000-23-152-H01-P
1.5 CPE contact hours
Application-Based Activity

Part II: Interactive Case: Critical Evaluation of Kidney Function

Universal Activity Number: 0217-0000-23-153-H01-P
1.5 CPE contact hours
Application-Based Activity

Release date: October 8, 2023
BCPS posttest submission deadline: 11:59 p.m. (Central) on April 8, 2024.
ACPE posttest submission deadline: 11:59 p.m. (Central) on October 8, 2026.

TO EARN CPE/RECERTIFICATION CREDIT FROM THIS FEATURE
Posttest access: Purchase the required posttests (see below); then go to www.accp.com and sign in with your e-mail address and password. PSAP in JACCP features are listed under My Products on your My Account page.
Technical support is available from 8 a.m. to 5 p.m. (Central) weekdays by e-mail at [email protected].

Release Date: October 08, 2023
BCPS Deadline: April 08, 2024
ACPE Deadline: October 08, 2026

Publication Year: 2023
Format: Online Test

CPE Credit

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

The American College of Clinical Pharmacy is approved by BPS as a provider for the recertification of BCPS.

BPS is an autonomous division of the American Pharmacists Association. To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for board certification examinations. BPS, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. BPS is totally separate and distinct from ACCP. For information about BPS specialty recertification the BPS recertification process, go to: www.bpsweb.org/

To receive recertification credit, posttests must be submitted prior to the recertification posttest deadline (see above). Only completed tests are eligible for credit; no partial or incomplete tests will be processed. You may complete one or all available posttests for credit.

The passing point to earn recertification credit is based on an expert analysis of the assessment items in each posttest. Any posttest submitted before the recertification test deadline that meets this passing point will earn recertification credits. These credits will be assigned as of the date of test submission and reported within 48 hours to BPS. For statements of recertification credit, visit www.bpsweb.org.

In accordance with BPS guidelines concerning remediation for products launched in 2024 and after, posttests that do not reach the passing point for recertification credit will generate a second-chance test option. This test will automatically appear in the learner’s My Account page and will have assessment items presented in a different order. To qualify for recertification credit, the second-chance test must be submitted before the recertification deadline stated above.

The ACCP Recertification Dashboard is a free online tool that can track recertification credits as they are earned through ACCP and schedule new opportunities for credits from upcoming ACCP professional development programs. Questions regarding the number of hours required for recertification should be directed to BPS at www.bpsweb.org.


Commercial Support

The American College of Clinical Pharmacy does not solicit or accept external commercial/financial support for its continuing pharmacy education activities. No commercial/financial support has been solicited or accepted for this activity.